Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Adv Lab Med. 2023 Nov 14;5(2):115-130. doi: 10.1515/almed-2023-0081. eCollection 2024 Jun.
ABSTRACT
Liver fibrosis is the result of chronic liver injury of different etiologies produced by an imbalance between the synthesis and degeneration of the extracellular matrix and dysregulation of physiological mechanisms. Liver has a high regenerative capacity in the early stage of chronic diseases so a prompt liver fibrosis detection is important. Consequently, an easy and economic tool that could identify patients with liver fibrosis at the initial stages is needed. To achieve this, many non-invasive serum direct, such as hyaluronic acid or metalloproteases, and indirect biomarkers have been proposed to evaluate liver fibrosis. Also, there have been developed formulas that combine these biomarkers, some of them also introduce clinical and/or demographic parameters, like FIB-4, non-alcoholic fatty liver disease fibrosis score (NFS), enhance liver fibrosis (ELF) or Hepamet fibrosis score (HFS). In this manuscript we critically reviewed different serum biomarkers and formulas for their utility in the diagnosis and progression of liver fibrosis.
PMID:38939201 | PMC:PMC11206202 | DOI:10.1515/almed-2023-0081
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
Serum biomarkers for liver fibrosis assessment
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Serum miR‑29 is increased in mice with early liver fibrosis Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis? Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease The diagnostic utility of FIB-4 as a non-invasive tool for liver fibrosis scoring among NAFLD patients: a retrospective cross-sectional study Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study COVID-19 in Individuals with Chronic Liver Diseases Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017-2018 Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis Chronic unpredictable mild stress increases serum aldosterone without affecting corticosterone levels and induces hepatic steatosis and renal injury in young adult male rats Association between the cardiometabolic index and NAFLD and fibrosis The transcription factor ZNF469 regulates collagen production in liver fibrosis Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease Alcohol use disorders and liver fibrosis: an update The Pan Immune Inflammatory Value in Relation to Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences The association between diverse serum folate with MAFLD and liver fibrosis based on NHANES 2017-2020 Angiocrine signaling in sinusoidal homeostasis and liver diseases Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease CD47, a novel YAP target gene, contributes to hepatic stellate cell activation and liver fibrosis induced by high-fat diet Role of prostaglandin E2 and its receptors in chronic liver disease FGL1 and FGL2: emerging regulators of liver health and disease Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids The deleterious effects and potential therapeutic strategy of fluorene-9-bisphenol on circadian activity and liver diseases in zebrafish and mice DIAGNOSTIC ACCURACY OF THE NON-INVASIVE MARKERS NFLS, NI-NASH-DS, AND FIB-4 FOR ASSESSMENT OF DIFFERENT ASPECTS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN INDIVIDUALS WITH OBESITY: CROSS-SECTIONAL STUDY Egr2 drives the differentiation of Ly6Chi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways Musculus senhousei peptides alleviated alcoholic liver injury via the gut-liver axis Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis The role and mechanism of SUMO modification in liver disease Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt Clinicopathological features of Sjogren's syndrome complicated with liver injury WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
Evidence Blueprint
Serum biomarkers for liver fibrosis assessment
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Serum biomarkers for liver fibrosis assessment
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Serum miR‑29 is increased in mice with early liver fibrosis Disease Progression-Related Markers for Aged Non-Alcoholic Fatty Liver Disease Patients Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis Transient Elastography Is the Best-Performing Non-Invasive Test of Liver Fibrosis in Obese Asian Patients with Non-Alcoholic Fatty Liver Disease: A Pilot, Cross-Sectional Study Diagnostic Accuracy of Vibration Controlled Transient Elastography as Non-invasive Assessment of Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease Biomarkers of liver diseases Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis? Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection Unconjugated hyperbilirubinemia may exacerbate certain underlying chronic liver diseases NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: a multi-center, retrospective study Application and Diagnostic Performance of Two-Dimensional Shear Wave Elastography and Liver Fibrosis Scores in Adults with Class 3 Obesity Quantification of collagen fiber properties in alcoholic liver fibrosis using polarization-resolved second harmonic generation microscopy Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease Liver fibrosis in pars cohort study: A large-scale study on the prevalence and correlated factors IL-23/IL-17 Axis in Chronic Hepatitis C and Non-Alcoholic Steatohepatitis-New Insight into Immunohepatotoxicity of Different Chronic Liver Diseases The diagnostic utility of FIB-4 as a non-invasive tool for liver fibrosis scoring among NAFLD patients: a retrospective cross-sectional study Research progress of traditional Chinese medicine in improving hepatic fibrosis based on inhibiting pathological angiogenesis Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis Diagnostic potential and pathogenic performance of circulating miR-146b, miR-194, and miR-214 in liver fibrosis Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study A Hospital Based Observational Study to Detect Non-Alcoholic Steatohepatitis by Acoustic Radiation Force Impulse in Individuals with Diabetes Mellitus and Metabolic Syndrome Hepatic Fibrosis Evaluated in Patients with Type 2 Diabetes with and without Chronic Kidney Disease COVID-19 in Individuals with Chronic Liver Diseases Extracellular Vesicles and Fatty Liver Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease Performance of non-invasive tests for liver fibrosis and resolution after bariatric surgery Alcoholic liver disease - 2023 Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease Factors Associated with Discordance in the Assessment of Fibrosis Stage between Transient Elastography and Liver Biopsy in NAFLD Patients Cellular senescence in liver diseases: From mechanisms to therapies Non-invasive visualization of liver fibrosis with [68Ga]Ga-DOTA-FAPI-04 PET from preclinical insights to clinical translation Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017-2018 Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study A Markov model of fibrosis development in Non-Alcoholic Fatty Liver Disease predicts fibrosis progression in clinical cohorts Chronic unpredictable mild stress increases serum aldosterone without affecting corticosterone levels and induces hepatic steatosis and renal injury in young adult male rats Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome Osr1-mediated mesothelial transition of liver mesenchymal cells exacerbates fibrotic liver damage The Value of Liver Biopsy and Histology in Liver Disease Diagnosis and Patient Care-a Pragmatic Prospective Clinical Practice Study Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study Higher ultra-processed food intake is associated with adverse liver outcomes: a prospective cohort study of UK Biobank participants Liver Stiffness Measurement is Useful in Predicting Type 2 Diabetes Mellitus Among Nonalcohol Fatty Liver Disease Patients Liver fat as risk factor of hepatic and cardiometabolic diseases Serum biomarkers predictive of cirrhosis in alcoholic liver disease as an alternative to ARFI-SW elastography Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review Association between the cardiometabolic index and NAFLD and fibrosis The transcription factor ZNF469 regulates collagen production in liver fibrosis Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients